Opendata, web and dolomites

RvD3-RAVIS

Novel Resolvin D3: its Role and Actions in the Resolution of Aortic Valvular Inflammation and Stenosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "RvD3-RAVIS" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 185˙857 €
 EC max contribution 185˙857 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2019-04-03

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 185˙857.00

Map

 Project objective

Aortic valve stenosis is a progressive inflammatory disorder with poor prognosis if left untreated. Currently the only available treatment is invasive surgical replacement of the valve, therefore new therapeutic strategies are needed. Resolution of inflammation is an active process orchestrated by endogenous specialized proresolving lipid mediators (SPM). These include the resolvins that actively promote catabasis via their potent actions in anti-inflammation, proresolution, tissue regeneration and pain reduction. Recently the complete stereochemistry of resolvin D3 (RvD3) was established. Given its highly potent anti-inflammatory and proresolving actions in murine models and with human cells its role and actions in aortic stenosis (AS) remains to be uncovered. Thus, a goal of this proposal is to elucidate endogenous resolution programs in human aortic valves and define the role and action of RvD3 in AS and calcification. To address this the candidate will employ LC-MS-MS based LM metabololipidomics combined with clinically relevant parameters as well as biochemical and cellular assessments in samples from AS patients. In addition, RvD3 will be used as treatment in a novel preclinical model of murine AS. Implementation of the proposed project will maintain and enhance the candidate’s position at the forefront in the field of resolution biochemistry with advances into valvular pathology. Unraveling the role of RvD3 and resolution programs in aortic inflammation and resolution may enhance current understanding of the molecular mechanism contributing to chronic cardiovascular inflammation and introduce a novel concept for the pathology AS. Furthermore, it may lead to novel therapeutic strategies with a potential to slow or halt the hemodynamic progression of stenosis via turning on resolution programs.

 Publications

year authors and title journal last update
List of publications.
2018 Marcelo H. Petri, Silke Thul, Teodora Andonova, Moritz Lindquist-Liljeqvist, Hong Jin, Nikolaos-Taxiarchis Skenteris, Hildur Arnardottir, Lars Maegdefessel, Kenneth Caidahl, Mauro Perretti, Joy Roy, Magnus Bäck
Resolution of Inflammation Through the Lipoxin and ALX/FPR2 Receptor Pathway Protects Against Abdominal Aortic Aneurysms
published pages: 719-727, ISSN: 2452-302X, DOI: 10.1016/j.jacbts.2018.08.005
JACC: Basic to Translational Science 3/6 2019-09-30
2017 Marcelo H Petri, Andrés Laguna-Fernandez, Hildur Arnardottir, Craig E Wheelock, Mauro Perretti, Göran K Hansson, Magnus Bäck
Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E −/− mice
published pages: 4043-4054, ISSN: 0007-1188, DOI: 10.1111/bph.13707
British Journal of Pharmacology 174/22 2019-09-30
2018 Andres Laguna-Fernandez, Antonio Checa, Miguel Carracedo, Gonzalo Artiach, Marcelo H. Petri, Roland Baumgartner, Maria J. Forteza, Xintong Jiang, Teodora Andonova, Mary E. Walker, Jesmond Dalli, Hildur Arnardottir, Anton Gisterå, Silke Thul, Craig E. Wheelock, Gabrielle Paulsson-Berne, Daniel F.J. Ketelhuth, Göran K. Hansson, Magnus Bäck
ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages
published pages: 1693-1705, ISSN: 0009-7322, DOI: 10.1161/circulationaha.117.032801
Circulation 138/16 2019-09-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RVD3-RAVIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RVD3-RAVIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

SIMIS (2020)

Strongly Interacting Mass Imbalanced Superfluid with ultracold fermions

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More